• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >What can we learn from herceptin((r)) trials in metastatic breast cancer?
【24h】

What can we learn from herceptin((r)) trials in metastatic breast cancer?

机译：从Herceptin（r）转移性乳腺癌试验中我们可以学到什么？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Herceptin((R)) (trastuzumab), an anti-HER2 monoclonal antibody, is the first oncogene-targeted therapy to be developed for the treatment of metastatic breast cancer. The Herceptin clinical trial program has demonstrated that treatment with Herceptin provides substantial clinical benefits when used either as monotherapy or in combination with a number of chemotherapeutic agents. Of note, accurate assessment of HER2 status is essential to ensure that the patients most likely to benefit from Herceptin are identified: patients with immunohistochemistry (IHC) 3+ or fluorescence in-situ hybridization (FISH)-positive disease gain the greatest clinical benefits. In addition, clinical benefits appear to be greater the earlier Herceptin is used, although there is currently no direct clinical evidence to indicate whether an initial strategy of combination therapy is better than monotherapy or vice versa. Herceptin has been shown to be generally well tolerated. The most severe adverse events are rare serious infusion-related reactions and cardiotoxicity. These adverse events can be managed by standard care and patients at risk can often be identified prior to the initiation of Herceptin treatment. Currently, Herceptin should be given until disease progression, but there could be benefit in continuing treatment beyond disease progression.
机译：Herceptin（R）（曲妥珠单抗）是一种抗HER2单克隆抗体，是开发用于治疗转移性乳腺癌的首个靶向癌基因的疗法。 Herceptin临床试验计划已经证明，以Herceptin进行单一疗法或与多种化疗药物联合使用时，其治疗效果可观。值得注意的是，准确评估HER2的状态对于确保识别出最有可能从赫赛汀获益的患者至关重要：免疫组织化学（IHC）3+或荧光原位杂交（FISH）阳性疾病的患者获得最大的临床益处。此外，尽管目前尚无直接的临床证据表明联合治疗的初始策略是否比单一治疗更好，反之亦然，但使用赫赛汀的临床益处似乎更大。已显示赫赛汀通常具有良好的耐受性。最严重的不良事件是罕见的严重输液相关反应和心脏毒性。这些不良事件可以通过标准护理进行管理，并且经常可以在开始赫赛汀治疗之前确定有风险的患者。目前，赫赛汀应在疾病进展之前服用，但继续治疗可能有益于疾病进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号